Dual Antiplatelet Therapy versus Thrombolytics in Stroke

Thrombolytics are the standard of care for acute stroke yet are not without risk. Join host, Geoff Wall, with guest, Jake Galdo, as they discuss combination aspirin and clopidogrel versus thrombolytics in mild stroke. The GameChangerThrombolytic use in mild stroke is common due to the time factor of administration, but data is mixed. New research has shown DAPT to be non-inferior to TPA. HostGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthJake Galdo, PharmD, MBA, BCPS, BCGPCourse Content and Developer, CEimpactManaging Network Facilitator, CPESN Health EquityCEO, Seguridad ReferenceChen H, Cui Y, Zhou Z, et al. Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial. JAMA. 2023;329(24):2135–2144. doi:10.1001/jama.2023.7827https://jamanetwork.com/journals/jama/article-abstract/2806532 Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Discuss how the inclusion and exclusion criteria impact the interpretation of the ARIMIS study 2. Describe the potential benefits of DAPT therapy compared to thrombolytic therapy in mild stroke0.05 CEU/0.5 HrUAN: 0107-0000-23-249-H01-PInitial release date: 7/31/2023Expiration date: 7/31/2024Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram